Qualmedica Research, LLC | Evansville, IN
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:
Participant must be able to swallow a tablet
For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
Participants must weigh at least 15 kilograms (kg)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,633 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
There will be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal